Related Experiment Video
Updated: Apr 6, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS
Summary
Sulfonylureas are common type 2 diabetes drugs, but can cause hypoglycemia. Careful patient management and monitoring of drug interactions can optimize their risk-benefit profile.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- Diabetes mellitus presents significant global health challenges due to rising prevalence and severe complications.
- Sulfonylureas are frequently prescribed as first-line pharmacotherapy for type 2 diabetes mellitus.
- Hypoglycemia is a primary risk associated with sulfonylurea use.
Purpose of the Study:
- To analyze the factors contributing to pharmacologically-induced hypoglycemia with sulfonylureas.
- To evaluate the risk-benefit balance of sulfonylureas in type 2 diabetes management.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic profiles of sulfonylureas.
- Analysis of patient-specific factors (age, behavior, organ function) influencing hypoglycemia risk.
- Assessment of drug-drug interactions associated with sulfonylureas.
Main Results:
- Hypoglycemia risk is multifactorial, influenced by drug properties and patient conditions.
- Hepatic or renal dysfunctions significantly increase hypoglycemia risk.
- Concurrent use of certain medications elevates the potential for dangerous drug interactions.
Conclusions:
- Effective management of type 2 diabetes with sulfonylureas requires careful consideration of patient factors and potential drug interactions.
- When these factors are meticulously controlled, sulfonylureas offer a comparable risk-benefit ratio to other oral antidiabetic agents.
- Optimizing sulfonylurea therapy involves proactive risk mitigation strategies to minimize hypoglycemia incidence.
More Related Videos
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:06Oral Hypoglycemic Agents: Glinides
961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
965
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
965
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
888
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
888
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K